Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia - Wikidata - wikimedia - TriplyDB

Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia

Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia

http://www.wikidata.org/entity/Q28565000

about

Origin and therapy for hypertriglyceridaemia in type 2 diabetes The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults.Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins.Maternal inheritance of severe hypertriglyceridemia impairs glucose metabolism in offspring.Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes.Lack of the Lysosomal Membrane Protein, GLMP, in Mice Results in Metabolic Dysregulation in Liver The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes.Lipoprotein metabolism in nonalcoholic fatty liver disease Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy Dyslipidemia in obesity: mechanisms and potential targets Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus Ectopic lipid storage and insulin resistance: a harmful relationship.The regulation of ApoB metabolism by insulin.Hyperlipoproteinemia type 3: the forgotten phenotype.A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Key differences between apoC-III regulation and expression in intestine and liver.The Different Faces of the Pancreatic Islet.Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes.A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells.Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial).Fructose metabolism and metabolic disease.The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.

P2860

Q26824004-19B32FE4-271A-435D-8D84-91565B9BC034 Q28072835-E8306501-CDB6-4182-B342-7CCA831B189D Q28077776-54B66487-9AF2-4915-BA21-774888C40573 Q33572201-5DE34458-2C63-4EF1-BE29-DFF17F7FC052 Q34473275-24E91C19-C2F2-4BAA-885C-30E4C2BEA07C Q34480492-B945935A-A729-4DEB-80E7-374DF84161AC Q34793857-D6B50B5C-0F2D-4CC3-9559-EA61CBBA25F9 Q35310272-6A95A736-6B71-48C9-A12A-4FECD3408B64 Q35644730-8FC81E88-8568-4AD1-9909-FDA08607610F Q35654453-3973DD41-4B67-4AA4-A44C-E0CE4F97BFD5 Q35860314-984C4C15-428B-40B5-B373-922C28AABB8E Q35881759-A9760C88-7CB5-4A5E-99F5-D2B8D33461B9 Q35915137-64DCE8A0-78CD-46D5-9A31-09FBF880C11B Q36573819-4F0473CF-94E5-404B-B8ED-372AF32A3E55 Q36682138-0134E5F1-ECBC-4A11-BF70-8D6B96D45D3A Q36843331-D01F1AE5-141F-482D-A726-5C89700E1066 Q36935534-2BCCD810-B47C-4924-B358-AA787D0EF942 Q36994072-2EA3C595-9806-4EB5-8244-FF7A19E75FAF Q37468412-CD34A03B-53B7-4291-B816-463EBCE03E93 Q38095619-158AFD31-172A-413F-827F-1802379E0802 Q38110665-1A3B3E45-EE2D-427A-8893-AE536E06BBE6 Q38235600-8F62C20B-94D7-4F27-9F8F-9C8454F98853 Q38616263-5D9CCE2C-1E6D-400F-85FF-9ADB619CFFC5 Q38664013-E8DDCFCA-98F3-4856-8E4C-C2E8B890F54D Q38944286-66E69FA4-C252-49D4-AA7D-0F2F6F67D46B Q39175545-CAC0A9A0-318D-447B-94D1-A4731DE5490F Q39346744-11C10CD0-45D1-4D7A-9434-44DE25477CC4 Q40350510-68263F74-6186-466C-A3AD-5B378492611C Q41293822-A10BBB96-5C79-484E-A925-689EF41B1DD8 Q44851403-A9400724-8599-4815-AF93-1BDF27CAC24F Q46803666-344070C8-CFE3-4EF9-9D0D-B1D4860B066B Q47246053-56A08856-D368-440D-B065-1C7B7A3FDEC3 Q47913074-7DBEBA31-6ABB-43BB-A0B0-9CBFA71F8210 Q49334569-065A02FF-A5F4-4610-ABFB-C8703DF4EA3A Q49498180-BE9DD64F-735B-41DC-8757-2853BE5DFD4F Q50194599-D8493300-CA89-4ACB-A767-6195AAAFD3B2

P2860

Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia

http://www.wikidata.org/entity/Q28565000

description

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

artículu científicu espublizáu en 2011

@ast

im März 2011 veröffentlichter wissenschaftlicher Artikel

@de

scientific journal article

@en

vedecký článok (publikovaný 2011/03/01)

@sk

vědecký článek publikovaný v roce 2011

@cs

wetenschappelijk artikel (gepubliceerd op 2011/03/01)

@nl

наукова стаття, опублікована в березні 2011

@uk

مقالة علمية (نشرت في مارس 2011)

@ar

name

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@ast

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@en

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@nl

type

label

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@ast

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@en

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@nl

prefLabel

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@ast

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@en

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@nl

P1433

Q28565000-EDD632D6-7EB7-4652-8CAB-A7524A4217E4

P1476

Q28565000-8A7B6F19-B73D-4AF6-BB74-906009631745

P2093

Q28565000-16AD645C-3B5C-4FD5-B846-CDF4F30FE42F

Q28565000-2C49780A-6421-488B-B930-21123A6520AC

Q28565000-38430B40-C2A4-42C3-B81C-CED4DF31C04C

Q28565000-4FAB4C9E-B40F-4601-9FEB-EA7E3C7D7CEE

Q28565000-50FAA722-D80A-4F2E-BF05-592F008036D3

Q28565000-62DB0F77-3D4E-4E95-8000-A11639174EA9

Q28565000-64090CAB-C5AD-4993-8813-11C9B0D1A1B6

Q28565000-6557E107-6EEC-4A42-80E6-9EEE2C5F1883

Q28565000-73E5E8A5-12F8-48F5-95FD-8FB92A8E2231

Q28565000-8646AE65-40A8-4220-9AEC-60E1F2A04B4F

P304

Q28565000-EED5163F-7F94-4316-9B4E-879299F44570

P31

Q28565000-CFFC23A5-BD23-44EC-BD3E-CC2C32A70088

P3181

Q28565000-C15B74E7-3FB7-4A50-BECB-A8DA6631AA6C

P356

Q28565000-9773B065-B0AF-4D00-95F0-EFF6CEB65F72

P407

Q28565000-AF0B8B22-3545-44F9-A974-9DEB7D29FE41

P433

Q28565000-3128EBF4-640A-4E2C-A9C4-2092209A132C

P478

Q28565000-47D588B9-4F80-4C94-833F-29B8F8FFB7F7

P50

Q28565000-AF846090-6623-4948-B6E4-F207E937C5EE

Q28565000-B231F359-7063-467C-BA62-2B4DFF46649D

P577

Q28565000-AFC965D2-84A7-4C75-A389-53E7FA7560CE

P698

Q28565000-81121DCB-3CA6-4E31-A4D1-63E3D9119C0E

P921

Q28565000-673f970a-22b4-42fe-82d0-a15c1b9e29fb

Q28565000-904B9524-9A36-43B6-8334-58D3B829F3AF

P3181

P356

ATVBAHA.110.220723

P1433

Arteriosclerosis, Thrombosis, and Vascular Biology

P1476

Transcriptional activation of ...... ibute to diabetic dyslipidemia

@en

P2093

An Verrijken

http://www.w3.org/2001/XMLSchema#string

Anne Muhr-Tailleux

http://www.w3.org/2001/XMLSchema#string

Carolina Huaman Samanez

http://www.w3.org/2001/XMLSchema#string

Daniel Duran-Sandoval

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Vallez

http://www.w3.org/2001/XMLSchema#string

Folkert Kuipers

http://www.w3.org/2001/XMLSchema#string

Gisèle Mautino

http://www.w3.org/2001/XMLSchema#string

Ilse Mertens

http://www.w3.org/2001/XMLSchema#string

Isabelle Berard

http://www.w3.org/2001/XMLSchema#string

Jan A. Kuivenhoven

http://www.w3.org/2001/XMLSchema#string

P304

513–519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2846712

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/ATVBAHA.110.220723

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Marja-Riitta Taskinen

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21183731

http://www.w3.org/2001/XMLSchema#string

P921